Literature DB >> 23842718

Use of a novel technology to track adherence to product use in a microbicide trial of short duration (MTN-007).

Cheng-Shiun Leu1, Marina Mabragaña, Rebecca Giguere, Curtis Dolezal, Alex Carballo-Diéguez, Ian McGowan.   

Abstract

Adherence measurement in microbicide trials is challenging. To decrease recall and social desirability bias, we used an interactive voice response system (IVR) in a rectal microbicide trial. Forty-six participants were asked to report product use daily for 1 week. Participants received an incentive per call plus a bonus for calling every day. We examined adherence to calling the IVR and to gel use; we compared the latter to applicator counts. Adherence to calling the IVR daily was high (mean = 89.9 %, SD = 20.7 %). Adherence to gel use per IVR was very good (mean = 90.7 %, SD = 19.1 %), and consistent with applicator counts in 80.4 % of cases. Neither adherence to calling nor gel use were associated with temporal factors like day calls started, number of days since first call, or weekday vs. weekend. Daily reporting allowed identification of irregular product use. IVR appears useful for daily reporting in brief trials.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23842718      PMCID: PMC4157755          DOI: 10.1007/s10461-013-0549-2

Source DB:  PubMed          Journal:  AIDS Behav        ISSN: 1090-7165


  20 in total

1.  Using daily interactive voice response technology to measure drinking and related behaviors in a pharmacotherapy study.

Authors:  Henry R Kranzler; Khamis Abu-Hasaballah; Howard Tennen; Richard Feinn; Kevin Young
Journal:  Alcohol Clin Exp Res       Date:  2004-07       Impact factor: 3.455

2.  Use of interactive voice response (IVR) technology in health research with children.

Authors:  Werner G K Stritzke; Justine Dandy; Kevin Durkin; Stephen Houghton
Journal:  Behav Res Methods       Date:  2005-02

Review 3.  Interactive voice response technology to measure HIV-related behavior.

Authors:  Kerstin E E Schroder; Christopher J Johnson
Journal:  Curr HIV/AIDS Rep       Date:  2009-11       Impact factor: 5.071

4.  Test of an interactive voice response intervention to improve adherence to controller medications in adults with asthma.

Authors:  Bruce G Bender; Andrea Apter; Dan K Bogen; Perry Dickinson; Larry Fisher; Frederick S Wamboldt; John M Westfall
Journal:  J Am Board Fam Med       Date:  2010 Mar-Apr       Impact factor: 2.657

5.  Reliability of adolescents' self-reported sexual behavior: a comparison of two diary methodologies.

Authors:  A M Minnis; N S Padian
Journal:  J Adolesc Health       Date:  2001-05       Impact factor: 5.012

Review 6.  The reporting of sensitive behavior by adolescents: a methodological experiment in Kenya.

Authors:  Barbara S Mensch; Paul C Hewett; Annabel S Erulkar
Journal:  Demography       Date:  2003-05

7.  Real-time adherence monitoring for HIV antiretroviral therapy.

Authors:  Jessica E Haberer; Josh Kahane; Isaac Kigozi; Nneka Emenyonu; Peter Hunt; Jeffrey Martin; David R Bangsberg
Journal:  AIDS Behav       Date:  2010-12

8.  Limitations of the dye-based method for determining vaginal applicator use in microbicide trials.

Authors:  Michele N Austin; Lorna K Rabe; Sharon L Hillier
Journal:  Sex Transm Dis       Date:  2009-06       Impact factor: 2.830

9.  A mixed methods and triangulation model for increasing the accuracy of adherence and sexual behaviour data: the Microbicides Development Programme.

Authors:  Robert Pool; Catherine M Montgomery; Neetha S Morar; Oliver Mweemba; Agnes Ssali; Mitzy Gafos; Shelley Lees; Jonathan Stadler; Angela Crook; Andrew Nunn; Richard Hayes; Sheena McCormack
Journal:  PLoS One       Date:  2010-07-21       Impact factor: 3.240

Review 10.  Adherence and its measurement in phase 2/3 microbicide trials.

Authors:  Elizabeth E Tolley; Polly F Harrison; Els Goetghebeur; Kathleen Morrow; Robert Pool; Doug Taylor; Stephanie N Tillman; Ariane van der Straten
Journal:  AIDS Behav       Date:  2010-10
View more
  5 in total

1.  Trajectory of use over time of an oral tablet and a rectal gel for HIV prevention among transgender women and men who have sex with men.

Authors:  Cheng-Shiun Leu; Rebecca Giguere; José A Bauermeister; Curtis Dolezal; William Brown; Ivan C Balán; Barbra A Richardson; Jeanna M Piper; Javier R Lama; Ross D Cranston; Alex Carballo-Diéguez
Journal:  AIDS Care       Date:  2018-10-14

2.  The Safety of Multiple Flexible Sigmoidoscopies with Mucosal Biopsies in Healthy Clinical Trial Participants.

Authors:  Wai Kan Chiu; Rhonda M Brand; Danielle Camp; Stacey Edick; Carol Mitchell; Sherri Karas; Amanda Zehmisch; Ken Ho; Randall E Brand; Janet Harrison; Steven Abo; Ross D Cranston; Ian McGowan
Journal:  AIDS Res Hum Retroviruses       Date:  2017-03-15       Impact factor: 2.205

3.  High levels of adherence to a rectal microbicide gel and to oral Pre-Exposure Prophylaxis (PrEP) achieved in MTN-017 among men who have sex with men (MSM) and transgender women.

Authors:  Alex Carballo-Diéguez; Ivan C Balán; William Brown; Rebecca Giguere; Curtis Dolezal; Cheng-Shiun Leu; Mark A Marzinke; Craig W Hendrix; Jeanna M Piper; Barbra A Richardson; Cynthia Grossman; Sherri Johnson; Kailazarid Gomez; Stephanie Horn; Ratiya Pamela Kunjara Na Ayudhya; Karen Patterson; Cindy Jacobson; Linda-Gail Bekker; Suwat Chariyalertsak; Anupong Chitwarakorn; Pedro Gonzales; Timothy H Holtz; Albert Liu; Kenneth H Mayer; Carmen Zorrilla; Javier Lama; Ian McGowan; Ross D Cranston
Journal:  PLoS One       Date:  2017-07-27       Impact factor: 3.240

Review 4.  Technologies for Medication Adherence Monitoring and Technology Assessment Criteria: Narrative Review.

Authors:  Madilyn Mason; Youmin Cho; Jessica Rayo; Yang Gong; Marcelline Harris; Yun Jiang
Journal:  JMIR Mhealth Uhealth       Date:  2022-03-10       Impact factor: 4.947

5.  Firmness Perception Influences Women's Preferences for Vaginal Suppositories.

Authors:  Toral Zaveri; Rachel J Primrose; Lahari Surapaneni; Gregory R Ziegler; John E Hayes
Journal:  Pharmaceutics       Date:  2014-09-10       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.